AstraZeneca PLC (AZNL.XC)

Compare

11,922.00

-76.00

(-0.63%)

As of 3:29:41 PM GMT. Market Open.

AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies

AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or immune-mediated diseases.

Zacks 1 hour ago

AZN

196170.KQ

BMRN
IgniteData launches cutting edge data integration platform for clinical trials at Cambridge University Hospitals

IgniteData has announced a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) and Cambridge University Hospitals NHS Foundation Trust (CUH) to launch its Archer tool for clinical data integration in an ongoing Phase 3 study sponsored by AstraZeneca. This collaboration marks a significant milestone in IgniteData's aim of transforming clinical trials through automation and digital innovation.

PR Newswire 3 hours ago

AZN

AZNCF
Eventful Monday For AstraZeneca - What's Going On?

On Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the CALYPSO Phase 3 trial designed to evaluate the efficacy and safety of eneboparatide in adults with chronic hypoparathyroidism. The study showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical significance at 24 weeks in adults with chronic hypoparathyroidism (HypoPT) compared to placebo. The primary endpoint is a composite of norma

Benzinga 3 hours ago

AZN

196170.KQ
Trending tickers: Nvidia, Berkshire Hathaway, Baidu, QinetiQ and AstraZeneca

The latest investor updates on stocks that are trending on Monday.

Yahoo Finance UK 4 hours ago

TCEHY

TCTZF

PNXGF
AstraZeneca Strikes up to $1 Billion Deal to Buy EsoBiotec

AstraZeneca (AZN) on Monday agreed to acquire Belgian biotechnology company EsoBiotec in a deal wort

PREMIUM
MT Newswires 5 hours ago

AZN
AstraZeneca adds ‘in vivo’ cell therapy capabilities with EsoBiotech deal

The British drugmaker is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer as well as autoimmune conditions.

BioPharma Dive 6 hours ago

AZN
AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio

The deal includes the Belgian biotech’s vivo cell-therapy platform, which modifies immune cells within the patient’s body, potentially increasing access to treatment and reducing costs.

The Wall Street Journal 7 hours ago

AZN

AZNCF
AstraZeneca boosts cancer therapies push with $1 billion EsoBiotec buy

(Reuters) -Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, seeking to accelerate the development of its cell therapy capabilities, particularly for cancer. "We are in the early stages in terms of clinical development, so our immediate plans will be to scale up the discovery efforts," Susan Galbraith, AstraZeneca's executive vice president for oncology R&D, told reporters on a call.

Reuters 8 hours ago

AZN
EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition

Acquisition includes EsoBiotec’s world-leading in vivo delivery platform with potential to transform cell therapyMONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE NEWSWIRE) -- EsoBiotec SA, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, today announced it has entered into a definitive agreement to be acquired by AstraZeneca (LSE/STO/Nasdaq: AZN). The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune

GlobeNewswire 8 hours ago

AZN

AZNCF
AstraZeneca Stock Scores RS Rating Upgrade

AstraZeneca ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.

Investor's Business Daily 2 days ago

AZN

AZNCF

LLY
INOVIO’s Covid-19 dMAb maintains in-vivo detection in 100% participants

Results saw all 24 healthy volunteers who made it to the 72-week mark still had effective levels of dMAB in their systems.

Clinical Trials Arena 2 days ago

AZN

GLDAF
AstraZeneca director says AI must be a “thought partner” in drug discovery

AstraZeneca’s senior director in oncology data science outlined how the company uses AI for drug discovery at a recent talk.

Pharmaceutical Technology 2 days ago

AZN
AstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer

WILMINGTON, Del., March 14, 2025--AstraZeneca and Erin Andrews have teamed up as part of a national public health campaign to educate and empower people to Get Body Checked Against Cancer. Erin is a passionate entrepreneur, national sports broadcaster, podcast host, hockey fan and wife — and cancer survivor.

Business Wire 2 days ago

AZN

AZNCF
AstraZeneca Stock Nears Buy Point After Long Run In Declining Market

AstraZeneca is Thursday's pick for IBD 50 Growth Stocks To Watch as the biopharmaceutical name is holding up relatively well in a declining market. AstraZeneca stock is nearing a buy point after climbing for seven straight weeks. The biopharmaceutical company develops drugs for cancer, immune, cardiovascular, kidney and rare diseases as well as vaccines.

Investor's Business Daily 3 days ago

AZN

AZNCF
Why Is CRISPR Therapeutics (CRSP) Up 0.4% Since Last Earnings Report?

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 3 days ago

CRSP

AZN
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know

In the latest trading session, Astrazeneca (AZN) closed at $75.57, marking a +1.79% move from the previous day.

Zacks 4 days ago

AZN
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.

Investor's Business Daily 4 days ago

AZN

AZNCF

LLY
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe

The latest decision makes Ionis/AstraZeneca's Wainzua the only approved drug in the EU for ATTRv-PN that can be self-administered monthly via an auto-injector.

Zacks 6 days ago

IONS

AZN
AstraZeneca and Ionis win EU approval for ATTR polyneuropathy

AstraZeneca and Ionis are intensifying their competition with Alnylam by securing an EU approval for Wainzua.

Pharmaceutical Technology 6 days ago

AZN
AstraZeneca reports positive outcomes from trial of Imfinzi

The perioperative treatment with Imfinzi plus FLOT showed improvement in event-free survival.

Clinical Trials Arena 7 days ago

AZN

Performance Overview

Return	AZNL.XC	FTSE 100
YTD	+14.06%	+6.26%
1-Year	+15.79%	+12.38%
3-Year	+25.01%	+17.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AstraZeneca PLC (AZNL.XC)

AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies

IgniteData launches cutting edge data integration platform for clinical trials at Cambridge University Hospitals

Eventful Monday For AstraZeneca - What's Going On?

Trending tickers: Nvidia, Berkshire Hathaway, Baidu, QinetiQ and AstraZeneca

AstraZeneca Strikes up to $1 Billion Deal to Buy EsoBiotec

AstraZeneca adds ‘in vivo’ cell therapy capabilities with EsoBiotech deal

AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio

AstraZeneca boosts cancer therapies push with $1 billion EsoBiotec buy

EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition

AstraZeneca Stock Scores RS Rating Upgrade

INOVIO’s Covid-19 dMAb maintains in-vivo detection in 100% participants

AstraZeneca director says AI must be a “thought partner” in drug discovery

AstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer

AstraZeneca Stock Nears Buy Point After Long Run In Declining Market

Why Is CRISPR Therapeutics (CRSP) Up 0.4% Since Last Earnings Report?

Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know

Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion

IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe

AstraZeneca and Ionis win EU approval for ATTR polyneuropathy

AstraZeneca reports positive outcomes from trial of Imfinzi

Performance Overview